Compare H2O America (HTO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs BIO-TECHNE Corp — how do they compare? H2O America trades at $63.61 (market cap $2.70B), while BIO-TECHNE Corp trades at $71.66 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 4.1× H2O America's market cap, and H2O America pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| HTO | TECH | |
|---|---|---|
Market Cap | $2.70B | $11.16B |
Sector | Technology | Health |
52-Week High | $65.43 | $72.12 |
52-Week Low | $44.44 | $43.31 |
Enterprise Value | $4.42B | $11.24B |
Dividend Yield | 2.73% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with strong technical indicators showing a bullish trend. The company maintains solid fundamentals with 12.87% net income margin and consistent earnings beats in recent quarters. Recent news highlights upcoming Q2 2026 earnings report on July 27, 2026, and institutional buying activity. Technical analysis shows support at $62-$64 with resistance at $65-$66 levels.
HTO presents a balanced investment case with 80% analyst buy ratings and a $63.50 consensus target. The water utility's stable revenue streams and dividend yield provide defensive characteristics, though valuation multiples appear full and RSI levels suggest near-term overbought conditions. Execution on $2.7 billion capex plan remains key for growth.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
